Postmenopausal hormone therapy and asthma onset in the E3N cohort.
Postmenopausal hormone therapy and asthma onset in the E3N cohort.
复制标题
DOI：
10.1136/thx.2009.116079
复制
发表时间：
2010-04
期刊：
影响因子：
10
通讯作者：
Clavel-Chapelon F
中科院分区：
文献类型：
--
作者：
Romieu I;Fabre A;Fournier A;Kauffmann F;Varraso R;Mesrine S;Leynaert B;Clavel-Chapelon F
流行病学研究表明，女性激素可能在哮喘中发挥作用，绝经期激素治疗（MHT或HRT）可能会增加绝经后妇女患哮喘的风险。唯一一项针对这一问题的前瞻性研究报告了发生哮喘的风险增加，这与雌激素单药治疗和雌激素/孕激素治疗相似。作为法国E3 N队列研究的一部分，从1990年至2002年，通过两年一次的问卷调查，前瞻性地研究了绝经后妇女使用不同类型的MHT与哮喘发作风险之间的关系。哮喘发作被认为是在基线时无哮喘的女性随访期间发生的哮喘病例的医学诊断时间。使用考克斯比例风险模型，调整潜在的混杂因素。在57，664名绝经期无哮喘的妇女中，在495，448年的随访中发现了569例哮喘事件。在近期使用者中，MHT与哮喘发作风险增加相关（HR= 1.20，95%CI 0.98-1.46）。仅在报告仅使用雌激素的女性中哮喘发作风险显著增加（HR= 1.54，95% CI 1.13-2.09），特别是从不吸烟的女性（HR= 1.80 95% CI 1.15-2.80）和在哮喘发作前报告过敏性疾病的女性（HR= 1.86 95% CI 1.18-2.93）。在这些亚组中也观察到与使用雌激素/孕激素相关的哮喘发作风险略有增加。绝经后单独使用雌激素与绝经期妇女新诊断哮喘的发生率增加有关。
Epidemiological studies have suggested that female hormones might play a role in asthma and that menopausal hormone therapy (MHT or HRT) might increase the risk of asthma in postmenopausal women. The only prospective study addressing this issue reports an increase in the risk of developing asthma which was similar for estrogen alone and estrogen/progestagen treatment. The association between the use of different types of MHT and the risk of asthma onset in postmenopausal women was investigated prospectively from 1990 to 2002 by biennial questionnaire as part of the French E3N cohort study. Asthma onset was considered to be the time of medical diagnosis of asthma cases occurring during the follow up of women who were asthma free at baseline. Cox proportional hazards models were used, adjusting for potential confounding factors. Among 57,664 women free of asthma at menopause 569 incident cases of asthma were identified during 495,448 years of follow-up. MHT was related to an increased risk of asthma onset (HR= 1.20, 95% CI 0.98–1.46) among recent users. The increase in risk of asthma onset was only significant among women reporting the use of estrogen alone (HR= 1.54, 95% CI 1.13–2.09).particularly in never smokers (HR= 1.80 95% CI 1.15–2.80) and women reporting allergic disease prior to asthma onset (HR= 1.86 95% CI 1.18–2.93). A small increase in the risk of asthma onset associated with the use of estrogen/progestagen was also observed in these subgroups. Postmenopausal use of estrogen alone was associated with an increased rate of newly diagnosed asthma in menopausal women.
登录
查看更多内容
影响因子：
--
作者：
Barr, RG;Wentowski, CC;Camargo, CA
通讯作者：
Camargo, CA
影响因子：
5
作者：
Romieu, I;Avenel, V;Clavel-Chapelon, F
通讯作者：
Clavel-Chapelon, F
影响因子：
5.8
作者：
Gavrila, A;Chan, JL;Mantzoros, CS
通讯作者：
Mantzoros, CS
影响因子：
6.1
作者：
Melgert, BN;Postma, DS;Hylkema, MN
通讯作者：
Hylkema, MN
影响因子：
--
作者：
Postma, Dirkje S.
通讯作者：
Postma, Dirkje S.